A man diagnosed with a brain tumour in Jersey just one month ago, has been given the chance of undergoing specialist therapy, after islanders raised £27,000 for him. Friends of
Following the new appointment at Advanced Oncotherapy Plc (LON:AVO) as Senior Independent Non-Executive Director, Mr Hans von Celsing talks to DirectorsTalk about his past experience, the present and his thoughts
Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announced this morning that yesterday the Directors below purchased ordinary shares of 25 pence in the
The use of reirradiation with intensity-modulated proton therapy (IMPT) yielded strong overall survival with limited toxicity in patients with thoracic tumors, according to a new study, potentially offering a new
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES 1. Identity of the issuer Advanced Oncotherapy or the underlying issuer plc of existing shares to which voting rights are attached: (ii) —————————–
Advanced Oncotherapy Plc (LON:AVO) is focused on delivering a more affordable, novel, proton-based radiotherapy system, based on technology originally developed at the world renowned CERN. The company is entering an
New projects will lead to improved diagnosis, reduced side effects of existing treatments, and the development of new, more effective ones The National Physical Laboratory (NPL), the UK’s National Measurement
Advanced Oncotherapy plc (LON:AVO), the developer of next generation proton therapy systems for cancer treatment, has told DirectorsTalk this morning that further to the financing agreement with Bracknor announced on
Advanced Oncotherapy’s Nicholas Serandour & Bracknor Investment’s Pierre Vannineuse discuss their £26 million financing agreement in this exclusive interview with Directorstalk
Pierre Vannineuse, CEO & Founding Partner of Bracknor Investment, commented on Advanced Oncotherapy LON:AVO: “AVO is a perfect match in our strategy to provide solid funding partnerships with investment grade
© 2024 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
